Eduardo R. A.
- Country
- Spain
- Department
- 172403: Hematologia
Research Overview
- Phase 1 Open-Label Dose Escalation and Expansion Study of CLN-049 in Acute Myeloid Leukemia with Measurable Residual Disease
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
- Efficacy and Safety of Oral Decitabine and Ivosidenib in Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 131 of 293 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating complex blood cancers, with particular focus on acute leukemias and their resistant forms. Their expertise extends to managing both relapsed and refractory cases, demonstrating significant involvement in advanced therapeutic approaches.
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Refractory Leukemias
Molecular Therapeutics
The investigator works with targeted therapies focusing on specific molecular pathways, including FLT-3 mutations and spliceosome mutations. Their work encompasses the evaluation of novel therapeutic agents targeting these specific genetic alterations.
- FLT-3 Mutation Analysis
- SF3B1 Mutations
- U2AF1 Mutations
Treatment Development
This clinician focuses on developing new therapeutic approaches for patients with higher-risk hematologic conditions. Their expertise includes evaluating oral medications and investigating novel treatment compounds for blood cancers.
- Novel Drug Development
- Oral Therapeutic Agents
- Treatment Response Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.